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1 The prostanoid-IP receptor may be unique among G protein coupled receptors in that it is
isoprenylated. In this study, we investigated the eects of the statins lovastatin and cerivastatin on
signalling by the mouse (m) IP and the human (h) IP receptors, over-expressed in human embryonic
kidney (HEK) 293 cells and by the hIP receptor, endogenously expressed in human
erythroleukaemia cells.
2 Both statins signi®cantly reduced IP receptor-mediated cyclic AMP generation and intracellular
calcium ([Ca2+]i) mobilization in a time and concentration dependent manner but had no eect on
signalling by the non-isoprenylated b2 adrenergic receptor or by the human prostanoid-TP receptor
isoforms.
3 Cerivastatin (IC50, 50 ± 90 nM) was signi®cantly more potent than lovastatin (IC50, 0.80 ± 4.2 mM)
in inhibiting IP receptor signalling.
4 Whereas IC50 values indicated that the hIP receptor was signi®cantly more sensitive than the mIP
receptor to the statins, the extent of inhibition of cyclic AMP generation by the mIP receptor was
signi®cantly greater than that of the hIP receptor to either statin, even at the highest concentrations used.
5 Pretreatment with either statin signi®cantly reduced IP receptor mediated desensitization of
signalling by the h.TPa, but not by the h.TPb, receptor isoform.
6 These data generated in whole cells point to the possibility that statin therapy may interfere with
IP receptor signalling in vivo; such interference may be extenuated under conditions where
circulating statin levels are elevated and may account, in part, for some of the pleiotropic aects of
the statins not attributed solely to their lipid lowering properties.
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Introduction
The prostanoid prostacyclin (prostaglandin (PG) I2) plays a
central role in the maintenance of vascular haemostasis
(Narumiya et al., 1999). It acts as a potent inhibitor of
platelet aggregation and as a vasodilator (Vane & Botting,
1995) and may confer a cytoprotective eect against tissue
injury in acute myocardial ischaemia or following hypoxic
exposure of vascular endothelial cells (Sakai et al., 1990).
Prostacyclin may also be important in the regulation of renal
blood ¯ow (Negishi et al., 1995) and acts as a lipolytic agent
in adipocytes (Chatzipanteli et al., 1992).
Prostacyclin signals through its speci®c G protein coupled
receptor (GPCR), termed the prostanoid IP receptor (Cole-
man et al., 1994). The IP receptor primarily couples to
activation of adenylyl cyclase (Boie et al., 1994), but may also
couple to other eector systems including phospholipase (PL)
C (Namba et al., 1994) and to inhibition of adenylyl cyclase
(Schwaner et al., 1995).
Isoprenylation is a post-translational lipid modi®cation of
proteins whereby carbon (C) 15 farnesyl or C20 geranylger-
anyl isoprenoids, derived from the mevalonate/cholesterol
biosynthetic pathway, are attached to speci®c cysteine
residues located in distinct carboxyl-terminal `isoprenylation
motifs' of proteins (Zhang & Casey, 1996). We recently
established that the IP receptor is isoprenylated within its
carboxyl terminal tail (C-tail) region (Hayes et al., 1999).
Whereas isoprenylation is not required for ligand binding, it
is absolutely required for IP receptor activation of adenylyl
cyclase and for ecient coupling to PLC (Hayes et al., 1999).
Lipid lowering agents encompass several classes of drugs
including the statins, which inhibit hydroxy methylglutaryl
coenzyme A (HMG CoA) reductase, and are widely used in
the treatment of hypercholesterolemia (Farnier & Davignon,
1998) and in the prevention of coronary heart disease
(Thompson, 1998; Maronm et al., 2000; Vaughan et al.,
2000). Reductions in low-density lipoprotein (LDL) cholester-
ol achieved with the statins (Hanefeld et al., 1999; Stein et al.,
1999) result in signi®cant reductions in morbidity associated
with coronary artery disease (Farnier & Davignon, 1998),
together with reductions in the incidence of stroke and total
mortality (Sacks et al., 1996; MacMahon et al., 1998). Since
mevalonate, the product of the HMG CoA reductase reaction,
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is the precursor of numerous nonsteroidal isoprenoid
metabolites in addition to cholesterol, including farnesyl and
geranylgeranyl pyrophos-phate, inhibition of HMG CoA
reductase through statin therapy has the potential to result
in pleiotropic eects not necessarily directly associated with
their cholesterol lowering properties but rather may also
inadvertently target isoprenylated proteins (Corsini et al.,
1999; Guijarro et al., 1998). Thus, in the present study we
investigated the eects of lovastatin and cerivastatin, a
recently developed HMG CoA reductase inhibitor, on IP
receptor function in human embryonic kidney (HEK) 293 cells
stably over-expressing the mouse (m) IP and human (h) IP
receptor and in the platelet-like human erythroleukaemia
92.1.7 (HEL) cells, which endogenously express the hIP
receptor at high levels. Our studies con®rm the functional
requirement for isoprenylation by both mIP and hIP receptors
and indicate that nM concentrations of cerivastatin signi®-
cantly impair IP receptor signalling.
Methods
Materials
Iloprost, [3H]-iloprost (15.3 Ci mmol71) and [3H]-CGP-12177
(41.0 Ci mmol71) were purchased from Amersham Pharma-
cia Biotech. Fura2/AM was purchased from Calbiochem.
Alprenolol and isoproterenol were purchased from Sigma.
[3H]-cyclic AMP (15 ± 30 Ci mmol71) was purchased from
American Radiochemicals Inc.
Transfections and stable cell lines
HEK.mIP and HEK.mIPSSLC and HEK.b2AR cell lines,
stably over expressing the wild type mIP receptor, the
isoprenylation defective mIPSSLC receptor and the human b2
adrenoceptor (b2 AR), respectively, have been previously
described (Hayes et al., 1999). The full-length hIP receptor
cDNA was subcloned into pHM6 (Roche) to generate the
plasmid pHM6:hIP. HEK.hIP cell lines stably overexpressing
the wild type hIP receptor in HEK 293 cells were established,
using pHM6:hIP, and characterized essentially as previously
described (Hayes et al., 1999). HEK.TPa10 cells and
HEK.TPb3 cells over-expressing the human prostanoid
thromboxane (TX) A2 receptor (TP) a and b isoforms,
respectively, have been previously described (Walsh et al.,
1998; 2000a). Cells were transfected with pCMV:Gaq as
previously described (Kinsella et al., 1997).
Measurement of cytotoxicity
Cytotoxicity assays in HEL cells and HEK 293 cells
preincubated for 20 h in the absence or presence of lovastatin
(1 and 10 mM) or cerivastatin (50 nM and 0.5 mM) were carried
out using CytoTox 96 Non-Radioactive Cytotoxicity Assay kit
(Promega) essentially as described by the manufacturer.
Measurement of cyclic AMP
To investigate the eect of the statins on ligand mediated
cyclic AMP generation, cells were preincubated for 16 h in
the presence of lovastatin (10 mM) or cerivastatin (0.5 mM);
alternatively, lovastatin (10 mM) or cerivastatin (0.5 mM) were
added to cells every 24 h over a period of 96 h. For time
course assays, cells were pre-incubated in the presence of
lovastatin (10 mM) or cerivastatin (0.5 mM) for times ranging
from 0 ± 24 h. For concentration response studies, cells were
pre-incubated with lovastatin (0 ± 20 mM) or cerivastatin (0 ±
5 mM) for 16 h. Thereafter, non viable cells were removed and
cyclic AMP assays were performed at 378C on viable cells as
previously described (Hayes et al., 1999) following stimula-
tion of cells for 10 min with the IP agonist, cicaprost (1 mM)
or the b2 AR agonists, alprenolol (10 mM) or isoprenaline
(1 mM). Levels of cyclic AMP produced by ligand stimulated
cells were expressed as fold stimulation over basal (fold
increase+s.e.mean, n=4).
Radioligand binding studies
Where speci®ed cells were pre-incubated in the presence of
10 mM lovastatin or 0.5 mM cerivastatin for 16 h. IP receptor
radioligand binding assays were carried on cell membranes
prepared from viable cells in the presence of 4 nM [3H]-
iloprost (15.3 Ci mmol71) as previously described (Hayes et
al., 1999). b2 AR assays were carried out on whole cells using
25 nM [3H]-CGP-12177 (41.0 Ci mmol71) at 148C for 3 h
using 100 mg protein in a ®nal volume of 100 ml, essentially as
described (Gagnon et al., 1998).
Measurement of intracellular Ca2+ mobilization
[Ca2+]i measurements were made in FURA2/AM preloaded
cells as previously described (Kinsella et al., 1997). Where
speci®ed, cells were pre-incubated for 16 h in the presence
of lovastatin (10 or 1 mM) or cerivastatin (0.5 mM or 50 nM)
and were stimulated with cicaprost (1 mM) or, as a control,
with the TP agonist U46619 (1 mM). For concentration
response studies, cells were pre-incubated with lovastatin
(0 ± 20 mM) or cerivastatin (0 ± 5 mM) for 16 h. In experi-
ments investigating the counter regulation of TP receptor
signalling by the IP receptor, HEK.TPa10 cells and
HEK.TPb3 cells, transiently co-transfected with Gaq, were
grown for 16 h in the presence or absence of lovastatin
(10 mM) or cerivastatin (0.5 mM); thereafter FURA2/AM
preloaded viable cells were stimulated with the IP receptor
agonist cicaprost (1 mM) followed by stimulation with the
TP receptor agonist U46619 (1 mM). Data presented in the
®gures are representative data from at least four indepen-
dent experiments and were calculated as mean changes in
intracellular Ca2+ mobilized (D[Ca2+]i+s.e.mean, nM; n=4)
as a function of time (seconds, s) following ligand
stimulation.
Data analyses
Radioligand binding data was analysed using GraphPad
Prism V2.0 programme (GraphPad Software Inc., San Diego,
CA, U.S.A.). Where appropriate, inhibitory concentration
(IC50) values were calculated using the GraphPad Prism V2.0
programme. Brie¯y, sigmoidal concentration response curves
were generated where X was the logarithm of statin
concentration and Y was the response (either cyclic AMP
fold increase or D[Ca2+]i mobilization, nM). IC50 values were
determined using the equation
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Y  Bottom fTopÿ Bottom=1 10log IC50ÿXg
where Top is the maximal response in the absence of statin,
and bottom is the maximal inhibitory eect in the presence of
the statins. Thereafter, data were plotted and are presented as
line graphs drawn as XY scatter plots where data points were
connected by smoothed lines. Statistical analyses were carried
out using the unpaired Student's t-test using the Statworks
Analysis Package. P-values 50.05 were considered to
indicate a statistically signi®cant dierence.
Results
The effect of the statins on IP receptor-mediated cyclic
AMP generation
The eects of lovastatin and cerivastatin on IP receptor
signalling were initially investigated in HEL cells, which
endogenously express the hIP receptor, and in HEK 293 cells
stably over-expressing the mIP receptor (HEK.mIP cells) or,
as a control, in HEK 293 cells over-expressing the human b2
AR (HEK.b2AR cells). Initial cytotoxicity studies established
that 64.2+1.0% (n=8) of HEK.mIP cells and 60.4+2.6%
(n=8) of HEL cells remained viable following 20 h exposure
to either statin with no signi®cant dierences observed
irrespective of the cell type or statin used. Thereafter,
measurement of ligand binding and intracellular signalling
was performed on viable cells only. Pre-incubation of cells
with lovastatin (Table 1) or cerivastatin (0.5 mM, data not
shown) for 16 h had no signi®cant eect on [3H]-iloprost
binding by IP receptors expressed in HEL cells or in HEK
293 cell lines or on [3H]-CGP-12177 binding by the b2 AR
expressed in HEK 293 cell lines.
In HEK.mIP cells, lovastatin (10 mM) and cerivastatin
(0.5 mM) pretreatment resulted in 84.6 and 88.1% reductions
in cicaprost mediated cyclic AMP generation, respectively
(Figure 1). In HEL cells, lovastatin and cerivastatin
pretreatment resulted in 54.1 and 56.1% reductions in
cicaprost mediated cyclic AMP generation, respectively
(Figure 1). It was noteworthy that the extent of inhibition
of cyclic AMP generation by the mIP receptor was
signi®cantly greater than that of the hIP receptor following
lovastatin (P50.0002) and cerivastatin (P50.0001) treat-
ment. Neither lovastatin (P40.2) nor cerivastatin (P40.1,
Figure 1) aected alprenolol mediated cyclic AMP generation
in HEK.b2 AR cells. Similarly, neither lovastatin (20 mM;
P40.33) nor cerivastatin (5 mM; P40.42) aected cyclic
AMP generation following stimulation of HEK.b2AR cells
with isoprenaline (1 mM).
Time dependent effects of the statins on IP
receptor-mediated cyclic AMP generation
In HEK.mIP cells both statins signi®cantly reduced cicaprost
mediated cyclic AMP generation following 8 h incubation
such that following 24 h incubation, the level of cicaprost
mediated cyclic AMP generation was reduced to 13.7 and
12.5% in the presence of lovastatin and cerivastatin,
respectively, relative to control, non-treated cells (Figure
2A,B). In HEL cells, both statins signi®cantly reduced IP
receptor signalling following 8 h incubation such that
following 24 h incubation, cicaprost mediated cyclic AMP
generation was reduced to 51.4 and 44.3% in the presence of
lovastatin and cerivastatin, respectively (Figure 2A,B). There
Table 1 Radioligand binding assays
Lovastatin [3H]-Iloprost bound
Cell type (10 mM) (fmol mg71 protein)a
HEK.mIP 7 3160+380
+ 2970+490
HEK.mIPSSLC 7 3573+510
+ 3672+600
HEK.hIP 7 1580+160
+ 1444+70
HEK 293 7 12.0+2.4
+ 12.5+0.9
HEL 7 44.3+2.6
+ 41.5+4.4
Lovastatin [3H]-CGP-12177 bound
Cell type (10 mM) (fmol mg71 protein)b
HEK.b2 AR 7 95.1+5.0
+ 99.7+7.3
HEK 293 7 14.9+3.5
+ 13.4+5.0
aRadioligand binding assays were carried out on membrane
fractions in the presence of 4 nM [3H]-iloprost. bRadioligand
binding assays were carried out on whole cells in the
presence of 25 nM [3H]-CGP-12177. Data are presented as
the mean+s.e.mean (n=4).
Figure 1 Eect of lovastatin and cerivastatin on IP receptor-
mediated cyclic AMP generation. HEK.mIP cells (mIP), HEL cells
(HEL), HEK.hIP cells (hIP), or HEK.b2AR cells (b2AR; inset to
panels) were preincubated with (+) or without (7) 10 mM lovastatin
(A) or with (+) and without (7) 0.5 mM cerivastatin (B) for 16 h
prior to harvesting. Cells were stimulated with 1 mM cicaprost or, in
the case of the b2AR, with 10 mM alprenolol. The asterisks (*)
indicate that cicaprost mediated cyclic AMP generation was
signi®cantly reduced in the presence of the statins compared to the
corresponding control cells, where ** indicates P50.01 and ***
indicates P50.001.
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were no statistical dierences in the overall level of inhibition
induced by 10 mM lovastatin compared with 0.5 mM cerivas-
tatin in either HEK.mIP cells or HEL cells; however, the
extent of inhibition of cyclic AMP generation by the mIP
receptor expressed in HEK.mIP cells was signi®cantly greater
than that of the hIP receptor expressed in HEL cells to either
lovastatin (P50.0002, 24 h) or cerivastatin (P50.0005, 24 h).
To establish whether repeat exposure to the statins could
cause further reductions in IP receptor signalling, fresh
aliquots of lovastatin or cerivastatin were added to the cells
every 24 h for up to 96 h (Figure 2C,D). No further
reductions in IP receptor mediated cyclic AMP generation
were observed following repeat exposure of HEK.mIP or
HEL cells to lovastatin or cerivastatin for 24, 48, 72 or 96 h.
However, the extent of inhibition of cyclic AMP generation
by mIP receptor was signi®cantly greater than that of the hIP
receptor expressed in HEL cells to lovastatin (P50.038 at
96 h) or cerivastatin (P50.05 at 96 h) treatment. Neither
statin aected signalling by the b2AR even following
prolonged incubation (24 h) with either lovastatin (P40.84)
or cerivastatin (P40.91; Figure 2A,B) or following repeat
exposure to either statin (Figure 2C,D).
Concentration dependent effects of the statins on IP
receptor-mediated cyclic AMP generation
From concentration response studies (Figure 3), IC50 values
for lovastatin and cerivastatin in HEK.mIP and HEL cells
were determined (Table 2). Whereas these IC50 values
indicated that the hIP receptor was signi®cantly more
sensitive than the mIP receptor to lovastatin (P50.0004) or
cerivastatin (P50.013), the extent of inhibition of cyclic
AMP generation by the mIP receptor was signi®cantly
greater than that of the hIP receptor to either statin
treatment, even at the highest concentrations used. Signalling
in HEK.mIP cells was reduced to 16.5 and 15% following
lovastatin (20 mM) and cerivastatin (5 mM; data not shown)
treatment, respectively, whereas signalling in HEL cells was
reduced to 40.3 and 29% following lovastatin (20 mM) and
cerivastatin (5 mM; data not shown) treatment, respectively.
In each case, the statins had no eect on alprenolol mediated
signalling by HEK.b2AR cells (Figure 3D,H).
To exclude the possibility that the apparent dierential
extent of inhibition of cyclic AMP generation by the mIP
receptor, expressed in HEK 293 cells, to that of the hIP
receptor, endogenously expressed in HEL cells, to statin
treatment may be due to unexplained dierences between the
host cells, we extended our studies to establish a stable HEK
293 cell line (HEK.hIP cells) over-expressing the hIP
receptor. Preincubation of HEK.hIP cells with lovastatin
(Table 1; P40.46) or cerivastatin (0.5 mM; P40.19; data not
shown) had no signi®cant eect on [3H]-iloprost binding.
Pretreatment of HEK.hIP cells with lovastatin (10 mM) or
cerivastatin (0.5 mM) for 16 h led to 50.7 and 46.9%
reductions in cicaprost mediated cyclic AMP generation,
respectively (Figure 1). From the concentration response
data, IC50 values of 0.8 mM lovastatin (Figure 3C, Table 2)
and 60 nM cerivastatin (Figure 3G, Table 2) in HEK.hIP cells
were determined. These IC50 values were consistent with
those previously found in HEL cells but which diered
Figure 2 Time dependent eect of lovastatin and cerivastatin on IP receptor-mediated cyclic AMP generation. HEK.mIP cells
(mIP), HEL cells (HEL) or HEK.b2 AR cells (b2AR) were preincubated with 10 mM lovastatin (A) or 0.5 mM cerivastatin (B) for 0 ±
24 h. Alternatively, cells were exposed to repeat doses of 10 mM lovastatin (C) or 0.5 mM cerivastatin (D) every 24 h for up to 96 h
prior to harvesting. Cells were stimulated with 1 mM cicaprost or, in the case of the b2AR, with 10 mM alprenolol.
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signi®cantly from those in HEK.mIP cells (Table 2).
Additionally, consistent with previous observations, the
extent of inhibition of cyclic AMP generation by the mIP
receptor expressed in HEK.mIP cells was signi®cantly greater
than that of the hIP receptor expressed in HEK.hIP cells to
lovastatin (P50.0001) and cerivastatin (P50.0001).
The effect of the statins on IP-receptor mediated [Ca2+]i
mobilization
We extended our studies to investigate the eect of the
statins on cicaprost mediated [Ca2+]i mobilization by the
mIP and hIP receptor or, as controls for a non-
isoprenylated receptor, in response to stimulation of
HEK.TPa10 cells, stably over-expressing the a isoform of
the human prostanoid TP receptor (TP), with the selective
TP agonist U46619. Stimulation of HEK.mIP cells, HEL
cells and HEK.hIP cells with cicaprost each resulted in an
increase in [Ca2+]i mobilization (Table 3). Cicaprost
mediated [Ca2+]i mobilization by HEK.mIP cells was
reduced to 66.8 and 22.4% in lovastatin (10 mM; 16 h) and
cerivastatin (0.5 mM; 16 h) treated cells, respectively (Table
3). From concentration response studies, IC50 values of
4.2 mM lovastatin (Figure 4A and Table 2) and 90 nM
Figure 3 Concentration dependent eects of lovastatin and cerivastatin on IP receptor-mediated cyclic AMP generation.
HEK.mIP cells (mIP; A and E), HEL cells (HEL; B and F), HEK.hIP cells (hIP; C and G), or HEK.b2 AR cells (b2AR; D and H)
were preincubated with 0 ± 20 mM lovastatin (A ±D) or 0 ± 1 mM cerivastatin (E ±H) for 16 h prior to harvesting. Cells were
stimulated with 1 mM cicaprost (A ±C, E ±G) or, in the case of the b2AR (D and H), with 10 mM alprenolol.
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cerivastatin (Figure 4D and Table 2) were determined in
HEK.mIP cells.
In HEL cells, cicaprost mediated [Ca2+]i mobilization was
reduced to 44.9 and 23.3% in lovastatin (10 mM; 16 h) and
cerivastatin (0.5 mM; 16 h) treated cells, respectively (Table 3).
From concentration response studies, respective IC50 values
of 3.1 mM lovastatin (Figure 4B and Table 2) and 65 nM
cerivastatin (Figure 4E and Table 2) were determined in HEL
cells. Stimulation of HEK.hIP cells with cicaprost resulted in
an increase in [Ca2+]i mobilization which was reduced to
41.9% in lovastatin (10 mM) treated cells, and to 45.3% in
cerivastatin (0.5 mM) treated cells (Table 3). From the
concentration response curves (Figure 4C,F), IC50 values of
lovastatin and cerivastatin in HEK.hIP were 2.6 mM and
63 nM, respectively (Table 2). Thus, the statins signi®cantly
impaired IP receptor mediated [Ca2+]i mobilization in HEL
cells, in HEK.mIP cells and in HEK.hIP cells with each cell
type being more sensitive to cerivastatin than lovastatin
treatment. In contrast, U46619 mediated [Ca2+]i mobilization
in HEK.TPa10 cells, transiently co-transfected with Gaq,
(Table 3) was not aected by pre-exposure of cells to either
lovastatin (Table 3; P40.4) or cerivastatin (Table 3;
P40.41).
The effect of the statins on IP receptor-mediated
desensitization of TP signalling
We have recently established that the TPa, but not the TPb,
isoform of the human TXA2 receptor (TP) is subject to direct
IP receptor-mediated desensitization (Walsh et al., 2000b).
Thus, in view of their inhibitory eects on IP receptor
signalling, we sought to investigate the eect of the statins on
IP receptor-mediated desensitization or counter-regulation of
TP receptor responses. Both HEK.TPa10 cells and
HEK.TPb3 cells showed ecient U46619 mediated [Ca2+]i
mobilization which was not signi®cantly aected by statin
treatment (Figure 5 and Table 4). Whereas stimulation of
HEK.TPa10 cells or HEK.TPb3 cells with cicaprost failed to
mediate a measurable rise in [Ca2+]i mobilization (Figure 5),
initial stimulation of HEK.TPa10 cells with cicaprost reduced
U46619 mediated signalling to 38% (P50.008; Figure 5A
and Table 4); in contrast, U46619 mediated signalling by
HEK.TPb3 cells was unaected by cicaprost (P40.82; Figure
5B and Table 4). Initial stimulation of lovastatin treated cells
with cicaprost reduced U46619 mediated signalling by
HEK.TPa10 cells to 54% (P50.05; Figure 5C and Table
4); however the lovastatin treated cells were signi®cantly less
sensitive (P50.029; Table 4) to cicaprost desensitization than
were HEK.TPa10 cells not treated with lovastatin. In
contrast, initial stimulation of cerivastatin treated cells with
cicaprost did not aect U46619 mediated signalling by
HEK.TPa10 cells (P40.137; Figure 5E and Table 4) and
thus, cerivastatin treated cells were signi®cantly less sensitive
(P50.0038; Table 4) to cicaprost desensitization than were
those HEK.TPa10 cells not treated with statin. At lower
concentrations, lovastatin (1 mM) or cerivastatin (50 nM) did
not aect cicaprost mediated desensitization of TPa signalling
in HEK.TPa10 cells (data not shown). Consistent with
previous data, U46619 mediated signalling by HEK.TPb3
cells was unaected by cicaprost (Table 4; P40.3 ± 0.68)
irrespective of pre-treatment of cells with or without statin
(Figure 5B,D,F; Table 4).
Discussion
In a recent study we established that the IP receptor may be
unique among GPCRs in that it is isoprenylated by a C15
farnesyl moiety at a cysteine residue within its C-tail region
(Hayes et al., 1999). Through site directed mutagenesis we
established that whereas isoprenylation was not required for
ligand binding by mIP receptor, it was absolutely required for
its ecient coupling to the eectors adenylyl cyclase and PLC
and, hence, for signalling by the IP receptor. In provisional
studies, inhibition of isoprenylation in the presence of the
HMG CoA reductase inhibitor lovastatin signi®cantly
reduced IP receptor mediated cyclic AMP generation (Hayes
et al., 1999). The statins as competitive inhibitors of HMG
CoA reductase, the rate limiting enzyme of cholesterol
biosynthesis, can be used to interfere with protein isoprenyla-
tion and therefore, represent important research tools in
elucidating the functional role of protein isoprenylation
(Maltese, 1990). In the clinical setting, the statins are widely
and eectively used in the treatment of hypercholesterolae-
mia, a major risk factor in the development of cardiovascular
disease, in particular atherosclerosis (Farnier & Davignon,
Table 2 IC50 values for lovastatin and cerivastatin
Cyclic AMP a [Ca2+]i
b
(IC50) (IC50)
Lovastatin Cerivastatin Lovastatin Cerivastatin
Cell type (mM) (nM) (mM) (nM)
HEK.mIP 3.5 80 4.2 90
HEL 0.85 50 3.1 65
HEK.hIP 0.8 60 2.6 63
Cells were incubated with 0 ± 20 mM lovastatin or 0 ± 5 mM
cerivastatin for 16 h. Thereafter, IP receptor mediated cyclic
AMPa and intracellular [Ca2+]i mobilization
b following
stimulation of cells with 1 mM cicaprost was evaluated.
Inhibitory concentration 50 (IC50) values for lovastatin (mM)
and cerivastatin (nM) were determined and are presented.
Table 3 Eect of the statins on IP- and TP-receptor
mediated [Ca2+]i mobilization
Growth condition
Control Lovastatin Cerivastatin
D[Ca2+]i D[Ca
2+]i D[Ca
2+]i
Cell type (nM) (nM) (nM)
HEK.mIPa 88.0+3.85 58.0+1.53** 19.7+0.61***
HELa 81.1+4.25 36.4+3.02** 18.9+1.9***
HEK.hIPa 139+6.36 58.2+3.61*** 63.0+1.56**
HEK.TPa10+Gaq
b 144+18.2 116+19.9 115+16.1
Cells were incubated without (Control) or with 10 mM
lovastatin (Lovastatin) or with 0.5 mM cerivastatin (Cer-
ivastatin) for 16 h. Thereafter, cells were stimulated with
1 mM cicaprosta or with 1mM U46619b and agonist mediated
changes in intracellular calcium mobilization (D[Ca2+]i (nM))
were determined. The asterisks indicate that cicaprost
mediated intracellular [Ca2+]i mobilization was signi®cantly
reduced in the presence of lovastatin or cerivastatin
compared to the corresponding control cells, where **
indicates P50.01 and *** indicates P50.001.
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1998). Thus, in view of the central role of the IP receptor
within the cardiovascular system coupled to our ®nding for a
functional requirement for isoprenylation of the IP receptor,
we sought to investigate in detail the eects of lovastatin and
cerivastatin on signalling by the IP receptor in whole cells.
Lovastatin serves as a reference compound and clinically is
known to be eective only at milligram concentrations
(Alberts et al., 1980; Hanefeld et al., 1999). On the other
hand cerivastatin, a fully synthetic pure enantiomer, has been
shown to be therapeutically active at microgram concentra-
tions (Stein et al., 1997; 1999; Hanefeld et al., 1999).
Thus, in the present study we investigated the eects of
lovastatin and cerivastatin on signalling by the mIP receptor,
stably over-expressed in HEK.mIP cells and by the hIP
receptor, endogenously expressed in HEL cells. To further
investigate the dierential sensitivity of the hIP receptor
versus the mIP receptor to the statins, the eects of lovastatin
and cerivastatin on signalling by the hIP receptor stably over-
expressed in HEK.hIP cells was also examined. Throughout
these studies, the eects of the statins on IP receptor
signalling were compared to signalling by the non-isopreny-
lated b2 AR or by TPa receptor. Initially, in view of the
established relative potencies of the statins under study, the
eect of 10 mM lovastatin and 0.5 mM cerivastatin on IP
receptor mediated cyclic AMP generation was investigated. In
HEK.mIP cells, both statins reduced mIP receptor signalling
to 10 ± 15% whereas in HEL and in HEK.hIP cells, hIP
receptor signalling was reduced to approximately 45% by
either statin. No signi®cant decreases in b2 AR signalling
were observed following exposure of HEK.b2AR cells to
either statin, con®rming that the observed eects of the
statins are targeted to the IP receptor itself and not to some
other component of the signalling system. Lovastatin or
cerivastatin pretreatment had no signi®cant eect on ligand
Figure 4 Concentration dependent eects of lovastatin and cerivastatin on IP receptor-mediated [Ca2+]i mobilization. HEK.mIP
cells (A and D), HEL cells (B and E) and HEK.hIP cells (C and F), were preincubated with 0 ± 20 mM lovastatin (A ±C) or 0 ± 1 mM
cerivastatin (D±F) for 16 h prior to harvesting. Data were calculated as changes in intracellular Ca2+ mobilized
(D[Ca2+]i+s.e.mean, nM) and are expressed as a percentage (%) relative to control, non-statin treated cells (D[Ca
2+]i+s.e.mean, %).
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binding by IP receptors expressed in HEL or HEK 293 cells
or by the control non-isoprenylated b2 AR, excluding the
possibility that the eects of the statins on IP receptor
signalling may be due to decreases in overall levels of IP
receptor expression. This was consistent with previous data
whereby disruption of IP receptor isoprenylation by site
directed mutagenesis had no signi®cant eect on its ligand
binding properties (Hayes et al., 1999).
Whereas both lovastatin and cerivastatin exhibited sig-
ni®cant time dependent reductions in mIP and hIP receptor
signalling, the extent of inhibition of cyclic AMP generation
by the mIP receptor was greater than that of the hIP receptor
to either statin even following their repeat administration
over a period of 96 h. Whereas IC50 values indicated that the
hIP receptor was signi®cantly more sensitive than the mIP
receptor to lovastatin (P50.0004) and cerivastatin
(P50.039), concentration response studies also indicated
that the extent of inhibition of cyclic AMP generation by
the mIP receptor was signi®cantly greater than that of the
hIP receptor to either statin, even at the highest concentra-
tions used. In contrast, signalling by the b2 AR was
unaected by either statin, irrespective of the concentration.
We next sought to investigate the eects of the statins on
IP receptor mediated [Ca2+]i mobilization. Initially we
examined the relative sensitivities of cicaprost mediated
[Ca2+]i mobilization by the mIP and hIP receptor to
lovastatin and cerivastatin and compared these eects to
those of the statins on U46619 mediated [Ca2+]i mobilization
by the non-isoprenylated TPa isoform. Consistent with
previous reports (Hayes et al., 1999; Van der Vuurst et al.,
1997), the mIP and hIP receptors exhibited ecient
mobilization of [Ca2+]i in response to cicaprost, con®rming
that IP receptors from both species couple to PLC activation.
Stimulation of HEK.TPa10, HEK.TPb3 or HEK 293 (Hayes
et al., 1999) cells with cicaprost failed to exhibit a rise in
[Ca2+]i mobilization indicating that the level of endogenous
IP receptor expressed in HEK 293 cells (Table 1) may not be
sucient to support a measurable rise in [Ca2+]i. These data
also con®rm that the cicaprost mediated [Ca2+]i response
observed in HEK.mIP and HEK.hIP cells was mediated
Figure 5 Eect of lovastatin and cerivastatin on IP receptor-mediated desensitization of TP receptor signalling. HEK.TPa10 cells
(A,C and E) and HEK.TPb3 cells (B,D and F), transiently co-transfected with Gaq, were preincubated with vehicle (A and B),
10 mM lovastatin (C and D) or 0.5 mM cerivastatin (E and F) for 16 h prior to harvesting. Cells were stimulated with 1 mM U46619
alone at 30 ± 50 s (U46619) or 1 mM cicaprost, at 30 ± 50 s, followed by 1 mM U46619, at 125 ± 175 s (Cicaprost, U46619).
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through IP receptors and not through other unrelated
prostanoid receptors. Both lovastatin and cerivastatin
exhibited time (data not shown) and concentration dependent
inhibitions of cicaprost mediated [Ca2+]i mobilization. From
concentration response studies, IC50 values indicated that the
hIP receptor is more sensitive to statin treatment than the
mIP receptor. Thus, taken together these studies investigating
the eects of the statins on IP receptor mediated cyclic AMP
generation and [Ca2+]i mobilization imply that there are
dierences in the structure/function properties and the
in¯uence of isoprenylation on the signalling behaviour of
the mIP and hIP receptors. In essence, these structure/
function dierences indicate that the extent of inhibition of
cyclic AMP generation due to statin treatment by the mIP
receptor is signi®cantly greater than that of the hIP receptor
whereas the IC50 data con®rm that the hIP receptor is more
sensitive than the mIP receptor to statin treatment.
Dierences in the signalling behaviour of the mIP and hIP
receptors have been previously alluded to in the scienti®c
literature (Smyth et al., 1998; Hayes et al., 1999). In studies
investigating the functional requirement for protein isopre-
nylation of the mIP receptor, we have previously established
that, through site directed mutagenesis of the critical cysteine
residue within the `CAAX' motif of mIP, leading to
generation of mIPSSLC, cicaprost mediated cyclic AMP
generation by mIPSSLC was almost completely abolished
whereas cicaprost mediated [Ca2+]i mobilization was sig-
ni®cantly reduced in a concentration dependent manner but
was not abolished (Hayes et al., 1999). On the other hand,
Smyth et al. (1998) reported that deletion of a substantial
portion of the C-tail of the hIP receptor including deletion of
the `CAAX' motif, generated a receptor that exhibited
identical coupling to adenylyl cyclase relative to the wild
type hIP receptor, but which exhibited substantially dimin-
ished ability to couple to PLC activation. A more complete
understanding of the species speci®c behaviour of the mouse
and human IP receptors will require detailed structure/
function analyses of the individual receptors, in particular
within their unique C-tail regions.
In studies investigating the intermolecular cross talk
between IP and TP receptor signalling, we have recently
established that the a, but not the b isoform, of the h.TP
receptor is subject to counter regulation or desensitization by
the IP receptor, mediated through direct protein kinase A
dependent phosphorylation of Ser329 within the unique C-tail
of TPa (Walsh et al., 2000b). In view of the inhibitory eect
of the statins on IP receptor signalling, we sought to establish
whether the statins may interfere in IP receptor mediated
desensitization or counter regulation of TP receptor
responses. Consistent with previous studies (Walsh et al.,
2000b), both HEK.TPa10 and HEK.TPb3 cells exhibited
ecient [Ca2+]i mobilization in response to U46619 which
was not signi®cantly aected by pretreatment of either cell
type with either statin. Whereas stimulation of HEK.TPa10
or HEK.TPb3 cells with cicaprost did not mediate signi®cant
or measurable rises in [Ca2+]i mobilization per se, initial
stimulation of cells with cicaprost signi®cantly desensitized
signalling by the TPa, but not the TPb, receptor. In
lovastatin treated cells, cicaprost signi®cantly reduced
[Ca2+]i mobilization by TPa, but not TPb; however, the
lovastatin treated HEK.a10 cells were signi®cantly less
sensitive (P50.029) to cicaprost desensitization than were
non-statin treated cells. In cerivastatin treated cells, cicaprost
failed to desensitize [Ca2+]i mobilization by the TPa receptor
in response to U46619; thus, cerivastatin signi®cantly
(P50.0038) impaired IP receptor mediated desensitization
of TPa responses. On the other hand, cerivastatin had no
aect on signalling by the TPb isoform.
Taken together, we have demonstrated that both lovastatin
and cerivastatin inhibit signalling by the mIP and hIP
receptor in whole cells in a time and concentration dependent
manner. In the case of cerivastatin, it was noteworthy that
the IC50 values for inhibition of IP receptor mediated cyclic
AMP generation and [Ca2+]i mobilization were 50 ± 90 nM
cerivastatin, concentrations which are re¯ective of the
maximum plasma concentration of 28.7 nM (13.8 mg L71)
and the 24 h area under the curve (or AUC0± 24) of 145 nM
(69.9 mg L71) achieved in vivo in humans for cerivastatin
following daily dosing of 0.8 mg for 28 days (Stein et al.,
1999). The physiological eects of statin treatment in vivo on
IP receptor signalling, IP receptor function and counter-
regulation of TP receptor signalling and control of vascular
haemostasis is at present unknown. Such physiological eects
may be particularly pronounced under conditions where
elevated blood concentrations of statins occur, in particular
for potent stains such as cerivastatin. Drugs which are either
inhibitors or substrates for cytochrome P450 ± 3A4 isotype,
such as cyclosporine A, erythromycin, clarithromycin,
nefazodone, protease inhibitors (Maronm et al., 2000) have
been shown to inhibit the metabolism and bio-transformation
of the statins in vivo, leading to elevated statin blood
concentrations (Corsini et al., 1999; Hanefeld et al., 1999).
This, in turn, increases the chances of adverse eects
associated with statin treatment, in particular liver toxicity
and muscle toxicity or myopathy (de®ned as muscle pain or
weakness). A 3 ± 5 fold increase in plasma levels of
cerivastatin have been observed in patients receiving
Table 4 The eect of the statins on IP receptor mediated
desensitization of TP receptor signalling
Changes in U46619 mediated [Ca2+]i mobilization
(D[Ca2+]i+s.e.mean, nM; n=4)
Treatment
HEK.TPa10 cells+Gaq 7Statin +Lovastatin +Cerivastatin
Stimulating agent (nM) (nM) (nM)
U46619 144+18.1 116+17.8 115+17.7
Cicaprost, U46619 55.0+3.03 65.9+1.93* 81.5+3.43**
HEK.TPb3 cells+Gaq
Stimulating agent
U46619 125+19.1 115+16.5 127+22.2
Cicaprost, U46619 118+19.3 128+11.5 102+16.2
HEK.TPa10 or HEK.TPb3 cells, transiently co-transfected
with Gaq, were pre-incubated for 16 h in the absence or
presence of lovastatin (10 mM) or cerivastatin (0.5 mM) and
then stimulated with U46619 (1 mM) alone or with cicaprost
(1 mM) followed by U46619 (1 mM). U46619 mediated Ca2+
mobilizations were represented as mean changes
D[Ca2+]i+s.e.mean, nM; n=4. The asterisks indicate that
cicaprost mediated desensitization of U46619 mediated
intracellular [Ca2+]i mobilization was signi®cantly reduced
in the presence of lovastatin or cerivastatin compared to the
corresponding control cells, where * indicates P50.05 and
** indicates P50.01.
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cyclosporine A (MuÈ ck, 1998); similar increases in blood levels
have been observed for other statins including pravastatin
and ¯uvastatin. Co-administration of the protease inhibitors
ritonavir and saquinavir with simvastatin and atorvastatin led
to increased statin plasma concentrations of 31.6 fold and 4.5
fold, respectively (Fichtenbaum et al., 2000). Other adverse
eects associated with statin therapy or following drug-drug
interactions in vivo include back pain, headache and acute
renal failure (Hanefeld et al., 1999). What correlation, if any,
exists between statin therapy and associated adverse eects
due to interference in IP receptor isoprenylation and IP
receptor signalling remains to be determined. However, given
our ®ndings that concentrations as low as 50 nM cerivastatin
can interfere with IP receptor function, it is possible that
clinical settings where elevated levels of statins, particularly
cerivastatin, occur could interfere in IP receptor signalling
and indeed with IP receptor-regulated vascular haemostasis.
It is also possible that other unexplained secondary
pleiotropic eects of statin treatment which are not related
to their lipid lowering properties, such as their documented
eects on endothelial function, in¯ammatory responses,
plaque stability, thrombus formation, decreased smooth
muscle cell migration and proliferation (Corsini et al., 1999)
may in part be attributed to interference in IP receptor
isoprenylation and function.
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